Terazosin: Nursing Drug Guide, BPH, Hypertension & First-Dose Syncope

Terazosin is available as Hytrin tablets and generic terazosin hydrochloride capsules (commonly 1, 2, 5, and 10 mg). Capsule and tablet products are not interchangeable milligram-for-milligram without prescriber review. Do not confuse terazosin with other quinazoline alpha-blockers during medication reconciliation.

Terazosin shares a quinazoline alpha-blocker class with doxazosin, tamsulosin, and other prostate or blood-pressure agents—verify drug name, dose, and bedtime versus morning timing on every pass.

FDA-approved uses are symptomatic benign prostatic hyperplasia (BPH) and hypertension. BPH therapy does not replace the need to screen for prostate cancer before and during treatment.

↔On a small screen, swipe or scroll sideways to see the full table.

Terazosin blocks postsynaptic alpha-1 adrenoceptors, relaxing prostate and bladder-neck smooth muscle in BPH and lowering peripheral vascular resistance in hypertension. Blood pressure begins to fall within about 15 minutes of an oral dose, with peak plasma levels near one hour and the greatest orthostatic blood-pressure effect often in the first few hours after dosing. That pharmacology explains why 1 mg at bedtime and slow titration are label requirements—not optional nursing preferences.

Label-based terazosin dosing always begins with 1 mg at bedtime for BPH and hypertension. Higher capsule strengths (2, 5, and 10 mg) are not indicated as initial therapy. Titrate stepwise only after the prior step is tolerated.

Onset, peak, duration, and half-life

↔On a small screen, swipe or scroll sideways to see the full table.

Missed dose: Take when remembered unless near the next scheduled dose; do not double doses. If several days are missed, contact the prescriber or pharmacist before restarting above 1 mg at bedtime.

Dosing must be verified against current prescribing information, prescriber orders, and local policy. Institutional protocols may vary.

Pretreatment checks

• Document baseline seated and standing blood pressure with an orthostatic blood pressure assessment when dizziness or recent falls are reported
• Confirm whether this is a first dose, step-up titration, or restart after interruption—each requires close follow-up during initial administration and heightened BP/symptom monitoring
• Review concurrent vasodilators—especially sildenafil or other PDE-5 inhibitors—and other antihypertensives such as verapamil, amlodipine, or losartan
• For BPH, verify prostate cancer screening status per prescriber plan
• Ask about planned cataract surgery—inform the team about current or prior alpha-blocker use (IFIS risk)

Contraindications

• Hypersensitivity to terazosin hydrochloride or formulation components

Important drug interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Important warnings

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Oral capsule or tablet (Hytrin and generics).

• Initiate and restart at 1 mg at bedtime per labeling; subsequent hypertension doses are often given in the morning after the first bedtime dose—follow the prescriber order
• Swallow capsules or tablets whole unless pharmacy confirms an alternate administration method for the specific product
• After first dose, dose increases, or restart, embed close symptom and vital signs monitoring—including orthostatic assessment and BP checks 2–3 hours post-dose when indicated
• Document orthostatic symptoms, blood pressure trends, and patient teaching on 12-hour driving restrictions

• Improved urinary stream, reduced nocturia, and less straining in BPH without symptomatic hypotension
• Gradual blood pressure reduction in hypertension without presyncope, syncope, or functional decline
• Tolerable mild fatigue or dizziness that resolves with slow position changes—not progressive orthostatic collapse after each dose

Escalate promptly when hemodynamic collapse, urologic emergency, or hypersensitivity emerges during terazosin therapy.

• Syncope or presyncope within the first few hours after dosing of a new dose, dose increase, or unsupervised restart
• Sustained symptomatic hypotension with dizziness, weakness, or falls after standing
• Priapism—painful erection lasting beyond usual duration
• Signs of serious hypersensitivity including angioedema or airway compromise
• New hepatic concern with jaundice, dark urine, or right upper quadrant pain—obtain liver tests and hold per protocol

↔On a small screen, swipe or scroll sideways to see the full table.

Terazosin overdose most likely presents as hypotension. There is no specific antidote listed in prescribing information. Because terazosin is 90–94% protein bound, dialysis is not expected to be beneficial.

Label-based management priorities

• Airway, breathing, and circulation support with continuous monitoring
• Treat hypotension with intravenous fluids and standard supportive measures per local emergency protocol
• Contact local poison control or medical toxicology services per facility protocol for refractory hypotension

• Terazosin vs doxazosin vs tamsulosin — overlapping alpha-blocker effects but different titration, timing, and product forms; verify drug name, dose, and bedtime versus morning orders on every pass
• Terazosin vs prazosin — both quinazoline alpha-blockers with first-dose hypotension risk; do not substitute one for the other without prescriber review
• Capsule strength confusion — 1, 2, 5, and 10 mg capsules look similar; independent double-check high-risk initiation doses
• Alpha-blocker duplication — do not combine terazosin with another alpha-blocker or duplicate BPH therapy unless explicitly ordered

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Blood pressure at end of dosing interval; consider measurement 2–3 hours after dosing when dizziness, palpitations, or orthostatic complaints occur
• Orthostatic symptoms, falls, and mental status during early therapy
• Voiding pattern and symptom relief in BPH; blood pressure trend in hypertension
• Liver tests when hepatic impairment is present or jaundice is suspected

Document

• Whether the dose was first bedtime initiation, titration step, or restart—and the close-follow-up plan for the first week
• Seated and standing BP with symptom correlation
• Patient teaching on 12-hour driving restriction after dose changes and slow position changes using teach-back

• Take the first dose and any restart at 1 mg at bedtime exactly as prescribed; do not skip directly to a higher dose after missing several days
• Stand up slowly and sit on the edge of the bed before walking—especially after the first dose or dose changes
• Avoid driving and hazardous tasks for 12 hours after the first dose, each increase, and restart
• Report fainting, severe dizziness, persistent painful erection, or swelling of the face/lips immediately
• Tell eye surgeons about current or prior alpha-blocker use before cataract surgery

Do not give and contact the prescriber/pharmacist when:

Hold parameters vary by institution and indication. Follow prescriber orders, pharmacy guidance, and local protocol.

Rehearse NCLEX-style clinical judgment practice for terazosin first-dose syncope and bedtime 1 mg initiation using a tabbed case (MAR, labs, vitals, and nursing notes), plus priority action, SATA cue recognition, trend interpretation, ordered response, cloze documentation, and matrix urgency matching tied to orthostatic hypotension.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.